28.6 F
Elizabeth City
Monday, March 8, 2021

A CLEAR Upfront Winner in Advanced RCC?

Must read

(MedPage Today) — Pembrolizumab (Keytruda) plus lenvatinib (Lenvima) improved survival outcomes and response rates as a first-line treatment for advanced renal cell carcinoma (RCC), the randomized phase III CLEAR study showed.
For the primary…
Read More

- Advertisement -

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

Latest article